We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Dynavax Technologies Corp (DVAX) Common Stock USD0.001

Sell:$10.94 Buy:$10.95 Change: $0.12 (1.05%)
Market closed |  Prices as at close on 23 July 2024 | Switch to live prices |
Change: $0.12 (1.05%)
Market closed |  Prices as at close on 23 July 2024 | Switch to live prices |
Change: $0.12 (1.05%)
Market closed |  Prices as at close on 23 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Contact details

2100 Powell Street, Suite 720
United States
+1 (510) 8485100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.43 billion
Shares in issue:
130.89 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • David Novack
    President, Chief Operating Officer
  • Ryan Spencer
    Chief Executive Officer, Interim Chief Financial Officer, Director
  • Kelly MacDonald
    Chief Financial Officer
  • John Slebir
    Senior Vice President, General Counsel
  • Robert Janssen
    Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.